Болезнь Кикучи: описание, диагностика и дифференциальный диагноз.

Kikuchi disease was described in 1972 in Japan. It is also known as histiocytic necrotizing lymphadenitis, Kikuchi necrotizing lymphadenitis, phagocytic necrotizing lymphadenitis, subacute necrotizing lymphadenitis, and necrotizing lymphadenitis. Kikuchi disease occurs sporadically in people with no family history of the condition. It was first described by Dr Masahiro Kikuchi (1935–2012) in 1972 and independently by Y. Fujimoto.

The signs and symptoms of Kikuchi disease are fever, enlargement of the lymph nodes (lymphadenopathy), skin rashes, and headache. In sixty to ninety percent of cases, lymphadenopathy presents in the posterior cervical lymph nodes with diameter enlargement typically being between one and two centimeters, but up to seven centimeters has been reported in literature. Occasionally, the supraclavicular and axillary lymph nodes become swollen as well. Rarely, enlargement of the liver and spleen and nervous system involvement resembling meningitis are seen. Often a bout of extreme fatigue can occur often taking hold during latter parts of the day and the affected person can be more prone to fatigue from exercise.

Some studies have suggested a genetic predisposition to the proposed autoimmune response. Several infectious candidates have been associated with Kikuchi disease. Many theories exist about the cause of KFD. Microbial/viral or autoimmune causes have been suggested. Mycobacterium szulgai and Yersinia and Toxoplasma species have been implicated. More recently, growing evidence suggests a role for Epstein Barr virus, as well as other viruses (HHV6, HHV8, parvovirus B19, HIV and HTLV 1) in the pathogenesis of KFD. In addition, serologic tests including antibodies to a host of viruses have consistently proven noncontributory and no viral particles have been identified ultrastructurally. KFD is now proposed to be a nonspecific hyperimmune reaction to a variety of infectious, chemical, physical, and neoplastic agents. Other autoimmune conditions and manifestations such as antiphospholipid syndrome, polymyositis, systemic juvenile idiopathic arthritis, bilateral uveitis, arthritis and cutaneous necrotizing vasculitis have been linked to KFD. KFD may represent an exuberant T cell mediated immune response in a genetically susceptible individual to a variety of nonspecific stimuli.

It is diagnosed by lymph node excision biopsy. Kikuchi disease is a self limiting illness which has symptoms which may overlap with Hodgkin's lymphoma leading to misdiagnosis in some patients. Antinuclear antibodies, antiphospholipid antibodies, anti dsDNA, and rheumatoid factor are usually negative, and may help in differentiation from systemic lupus erythematosus.

The differential diagnosis of Kikuchi disease includes systemic lupus erythematosus (SLE), disseminated tuberculosis, lymphoma, sarcoidosis, and viral lymphadenitis. Clinical findings sometimes may include positive results for IgM/IgG/IgA antibodies. For other causes of lymph node enlargement, see lymphadenopathy.

No specific cure is known. Treatment is largely supportive. Nonsteroidal anti inflammatory drugs (NSAIDs) are indicated for tender lymph nodes and fever, and corticosteroids are useful in severe extranodal or generalized disease. It is mainly a disease of young adults (20–30 years), with a slight bias towards females. The cause of this disease is not known, although infectious and autoimmune causes have been proposed. The course of the disease is generally benign and self limiting. Lymph node enlargement usually resolves over several weeks to six months. The recurrence rate is about 3%. Death from Kikuchi disease is extremely rare and usually occurs due to liver, respiratory, or heart failure.